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suffered from coronary heart disease (including stable angina pecto-
ris, unstable angina pectoris and acute myocardial infarction) and 80
healthy people from January 2013 to December 2014 were detected.
The data were analyzed by SPSS 21.0.
RESULTS The levels of serum CRP was 13.053.68mg/L and blood Hcy
was 21.178.63 mmol/L in patients with coronary heart disease were
higher than those in the control group(5.021.60 g/L, 8.152.03
mmol/L), the differences were statistically signiﬁcant(P <0.05). The
levels of serum CRP and blood Hcy in the acute myocardial infarction
subgroup of coronary heart disease patients(19.623.03 mg/L,
32.107.02 mmol/L) were higher than those in the unstable angina
pectoris subgroup(12.986.11 mg/L, 20.826.04 mmol/L)(P <0.05);
while, the levels of serum CRP and blood Hcy in the unstable pectoris
angina subgroup were higher than those in the stable angina pectoris
subgroup[(7.654.81) mg/L,(14.014.30) mmol/L], the differences
were statistically signiﬁcant (P <0.05).
CONCLUSIONS The levels of serum CRP and blood Hcy are high
expression in patients with coronary heart disease, and their expres-
sion level can be used as predictors to prompt the severity and type of
coronary heart disease.
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Long-term follow-up study of peripheral blood EMPs, EPCs levels in acute
coronary syndrome patients with or without diabetes
Yashu Kuang,1 Ying Li1
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Tongji University
OBJECTIVES Explore the levels of peripheral blood CD144þ / Annexin
Vþ EMPs, EPCs in patients of acute coronary syndrome (ACS) with or
without diabetes during long-term follow-up. Disscuss the relation-
ship among EMPs, EPCs, coronary artery acute ischemic events and
Abnormal glucose metabolism.
METHODS Study included 66 patients with acute coronary syndrome
(ACS) according to the coronary angiography. Based on clinical
symptoms and cardiac marker levels, the patients were divided into two
groups, A group:diabetes mellitus, acute coronary syndrome (ACS)
(n¼45), B group: acute coronary syndrome (ACS) (n¼21). Two groups of
patients were given drug treatment and atorvastatin and followed up
for 6 months. Respectively, test the levels of CD144þ Annexin Vþ
EMPs, EPCs in peripheral blood and clinical indexes, the presence of
ischemic symptoms before and after the follow-up.
RESULTS During the 6 months follow-up, all of the patients have no
abnormally elevated myocardial markers, sudden death due to coro-
nary heart disease (CHD) and again revascularization readmission to
the hospital clinical events. The level of CD144þ / Annexin Vþ EMPs
has no signiﬁcant difference before and after follow-up between the
two groups. However, no matter A or B, the level of CD144þ / Annexin
Vþ EMPs before follow-up was signiﬁcantly higher than after follow-
up (P < 0.05), and before and after follow-up there is no correlation
between glycosylated hemoglobin and EMPs in group A. The level
of EPCs of group A was signiﬁcantly higher than that of group B
(P < 0.05), and it was positively correlated to glycosylated hemoglobin
(r¼0.457). After follow-up, The level of EPCs of group A was signiﬁ-
cantly lower than that of group B (P < 0.05), and it was negative
correlated to glycosylated hemoglobin (P < 0.05, r ¼ -0.365). However,
no matter A or B, the level of EPCs before follow-up was signiﬁcantly
higher than after follow-up (P < 0.05).
CONCLUSIONS No matter combining diabetes mellitus or not, acute
ischemic events caused endothelial dysfunction is the dominant factor of
peripheral blood EMPs levels, also the main cause of activating repair
mechanisms to promote EPC mobilization. Diabetes patients in acute
coronary events release more EPCs, which are positively related with
glycosylated hemoglobin levels. But when atherosclerotic plaque turns to
stable, the ability of repairing is much lower in patients with diabetes,
and has negative correlation with glycosylated hemoglobin levels
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Adiponectin stabilizes aortic plaques in ApoE-/- mice via regulating the
level of autophagy
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OBJECTIVES Adiponectin (APN), an adipose-derived adipokine, offers
anti-atherogenic effects although the precise mechanism remains un-
clear. Autophagy reported as the major intracellular degradation systemcan be induced in stress conditions, such as atherosclerosis and oxida-
tive stress. This study was designed to examine the correlation between
APN and autophagy in apolipoprotein E-deﬁcient (ApoE-/-) mice.
METHODS Adult ApoE-/- mice were fed a high fat diet for 12 weeks.
After 8 week feeding, mice were treated with 10 ug/kg APN or vehicle
every day for 4 weeks. The size of aortic plaque was measured by oil
red O staining and autophagosomes were detected by transmission
electron microscope. Western blot was used to evaluate the expres-
sion of autophagy maker protein, LC3II.
RESULTS The size of aortic plaque was reduced by APN. And the
levels of autophagosomes decreased in APN group compared with
control group. Furthermore, APN also decreased LC3II and LC3II/I
protein expression ratio.
CONCLUSIONS These data suggest the autophagy in ApoE-/- mice
caused by high diet could be ameliorated by APN.
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Establishing the renalase gene low-expression modal in cardiac tissue of
Sprague-Dawley rats via lentivirus-mediated RNA interference technology
Xiaogang LI, Weihong Jiang
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OBJECTIVES Renalase is a novel secretory amino oxidase and expressed
in kidney and heart. To research the protective mechanism of renalase in
local heart tissue, we established the low-expression renalase model with
lentivirus-mediated RNA interference technology.
METHODS Three renalase-targeting oligonucleotides were designed
after analyzing the mRNA of renalase. Lentivirus particles were pre-
pared by LV expression Systems (using the trono 3 plasmid component
system), and then, LV-RNLS-shRNAs and LV-NC-shRNA were respec-
tively transfected into H9C2 cells in different culture dishes. The
optimal oligonucleotide was screened by real-time PCR and western
blotting. The renalase gene low-expression in the heart tissue of rats
via pericardial cavity injection. And real-time PCR andwestern blotting
were used to detect renalase gene expression in the heart.
RESULTS In the cell screening experiment, the efﬁcacy of the inhibition
of renalase mRNA expression was 93.7%, and that of renalase protein
expression was 83.1% in H9C2 cells. When the oligonucleotide was
injected into the pericardial cavities of the SD rats on the 10th day, it
inhibited 63.9% of the expression of renalase protein in the heart tissues.
CONCLUSIONS LV-Rnls-RNAi (19813-1) can be used to establish an
optimal renalase low-expression model for the subsequent experiments.OTHERSOTHERS
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OBJECTIVES The relative efﬁcacy and safety of non-vitamin K antag-
onist oral anticoagulants(NOACs) against warfarin have been assessed
for stroke prevention in atrial ﬁbrillation(AF) in several clinical sub-
groups. However, no pooled analysis has been undertaken across the
four landmark phase 3 randomized controlled trials (RCTs) to assess the
effects of all NOACs against warfarin in the subgroup of patients with AF
and heart failure (HF). We performed a systemic review and meta-
analysis of RCTs to determine the relative efﬁcacy and safety of NOACs
against warfarin among subgroup patients with AF and HF. Additionally,
we compared outcomes between AF patients with HF and without HF.
C270 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 6 , S U P P L S , 2 0 1 5METHODS A comprehensive literature search was conducted using
the Cochrane Library, MEDLINE, and Scopus databases from inception
to April 2015 without language restrictions. The following search
terms were used: (dabigatran OR rivaroxaban OR apixaban OR edox-
aban) AND (atrial ﬁbrillation OR heart failure). The available data were
extracted from the main trial publications, subgroup analyses, or
supplemental appendices. Statistical analyses were performed using
Revman 5.3 software.
RESULTS Four RCTs were identiﬁed and included in the present
study: 19122 patients with AF and HF were allocated to a NOAC (13384
receiving single/high-dose NOAC), and 13390 to warfarin. Single/high-
dose NOACs signiﬁcantly reduced the incidence of stroke or systemic
embolic events by 14% (Odds Ratio [OR]: 0.86, 95%Conﬁdence inter-
val [CI]: 0.76-0.98). Low-dose NOACs had comparable efﬁcacy to
warfarin for the stroke or systemic embolic events (OR 1.02; 95%CI:
0.86-1.21). A 24% reduction in major bleeding was seen with single/
high-dose NOACs, compared with those with warfarin (OR: 0.76, 95%
CI: 0.67-0.86). For low-dose NOACs, the OR for major bleeding was
0.64 but without signiﬁcant difference(95%CI: 0.38-1.07). Among the
42361 patients allocated to a NOAC, the outcomes were compared
between AF patients with HF and those without HF. Regardless of
high- or low-dose NOAC regimes, the incidences of both major
bleeding and the composite of stroke or systemic embolism in AF
patients with HF were similar to those without HF. In patients with AF
and HF, a 41% reduction in intracranial bleeding was observed (OR:
0.59, 95%CI: 0.40-0.87), perhaps driven by differences in comorbid-
ities between both groups.
CONCLUSIONS Among AF patients with HF, single/high-dose NOACs
have both favorable efﬁcacy and safety proﬁle compared with
warfarin. Low-dose regimens had similar efﬁcacy and safety as
warfarin. NOACs were similarly effective or even safer in AF patients
with HF compared to those without HF.
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The autophagy in neuron injury after cardiopulmonary resuscitation in rats
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OBJECTIVES Recent studies show the existence of autophagy in ce-
rebral ischemia; however, no studies have been found to examine the
role of autophagy in cerebral injury after cardiopulmonary resuscita-
tion (CPR). This study was to determine the role of autophagy in rats
model of ventricular ﬁbrillation (VF)/CPR.
METHODS Experiment 1:48 adult Wistar rats were subjected to VF by
an external transthoracic alternating current, left untreated for 6
minutes, and then administered CPR to observe the existence of
autophagy after return of spontaneous circulation (ROSC). Experi-
ment 2:72 rats were pretreated with intraperitoneal injections of
either saline (Control group), the autophagy inducer rapamycin
(Rapamycine group) or the autophagy inhibitor 3-methyladenine (3-
MA group) after ROSC at once to evaluate the contribution of auto-
phagy to neuronal injury after ROSC.
RESULTS Our results showed that autophagy activation attenuated
2 to 4 hours after ROSC and was related to the decrease in 5’-AMP-
activated protein kinase (AMPK) activity after ROSC. Rapamycine
treatment signiﬁcantly increased the expression of LC3-II and Beclin-1
after ROSC, attenuated the activation of casepase-3, promoted neuron
survival and decreased neuron apoptosis, and improved the neuro-
logical deﬁcit score after CPR. In contrast, 3-MA pretreatment signif-
icantly attenuated the expression of LC3-II and Beclin-1 and worsened
the neurological outcome after ROSC.
CONCLUSIONS Autophagy activation after ROSC shows remarkable
tolerance to VF/CPR ischemic insults, and improves neurological
outcomes.
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OBJECTIVES Prompt and proper ﬁeld resuscitation is vital for survival
from out-of-hospital cardiac arrest (OHCA). Return of spontaneous cir-
culation (ROSC) in the ﬁeld is one of the most important determinantscontributing to survival and favorable neurological outcomes following
OHCA. However, nearly one third of the survivors in our site were pa-
tients without ROSC achieved in the ﬁeld. In this study we described the
demographics, pre-hospital characteristics and outcomes of patients with
OHCA in our resuscitation research center, who were treated on scene
and transported to hospitals, and compared survivors who did and did
not have ROSC in the ﬁeld, as well as those who met the universal
Termination of Resuscitation (TOR, no ROSC, not EMS witnessed, and
not shocked)) criteria in the ﬁeld.
METHODS Resuscitation Outcomes Consortium (ROC), is a clinical
research network consisting of eleven regional centers and a data coor-
dinating center in North America that has registry systems and conducts
multi-center clinical trials focusing on OHCA and severe trauma. Its goal
is to evaluate strategies for pre-hospital treatment of patients with OHCA
or life-threatening trauma. Between 2006 throughout April 2011, a total
of 10,994 non-traumatic OHCA cases were screened and enrolled in
Dallas Fort Worth (DFW) ROC site in Texas. We included cases
aged 18years with non-traumatic OHCA treated and transported to a
hospital within DFW ROC site. Demographic characteristics, key pre-
hospital factors and resuscitative interventions in the ﬁeld, for all these
treated and transported cases, including survivors with and without
ROSC, as well as those who met TOR, were reported.
RESULTS Included were 5,099 OHCA cases; 83.2% (4,243) were pa-
tients without ROSC in the ﬁeld, of which 66.6% (2,827) met TOR
criteria in the ﬁeld but still were treated and transported. Of treated
cases, 5.6% (287) survived to hospital discharge; of the 94.4% (4,812)
who died, 82.6% (3,975) died in the Emergency Department, while
17.4% (837) died in the hospital. Further analysis of the survivors
showed that 72.5% (208) of the survivors had ROSC in the ﬁeld, and
27.5% (79) did not. Of interest, 10.8% (31) of survivors met TOR
criteria, accounting for 1.1% of this special population. EMS immediate
resuscitation attempt on witnessed arrest(OR 4.350, 95%CI 1.125-
16.819), shock-able initial rhythm (OR 3.053, 95%CI 1.079-8.643), and
advanced airway management(OR 0.329, 95%CI 0.104-1.041) were top
three signiﬁcant factors to predict survival of OHCA victims without
ROSC in the ﬁeld. Of concern, 1.7% (47/2827) of victims who met TOR
criteria presented initial shock-able rhythm but no shocks were
delivered in the ﬁeld by EMS personnel.
CONCLUSIONS In the DFW ROC site, 27.5% of OHCA survivors were
patients without ROSC achieved in the ﬁeld and 10.8% of the survi-
vors met Termination of Resuscitation criteria in the ﬁeld. Our data
suggest that all treated OHCA patients should be transported to the
hospital.GW26-e1558
Salicylic acid renders aspirin resistance via breaking the functional balance
of COX-1/COX-2 in diabetic mice
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OBJECTIVES Aspirin resistance (AR) has become a serious clinical
concern. Diabetes is an established risk factor of AR, but the key
mechanisms remain elusive. The objective of this study was to un-
cover whether there was an underlying link between pathogenic
accumulation of salicylic acid (SA), the major metabolite of aspirin,
and AR in the diabetic state.
METHODS One hundred 8-week-old female C57BL/6 mice were
randomly divided into normal control group (n¼20) and high-fat diet
and streptozotocin (HFD/STZ) induced diabetic group (n¼80). The
diabetic model mice were then randomly divided into four groups and
treated respectively with vehicle (0.5% CMC-Na), aspirin (dissolved in
0.5% CMC-Na), equal molar volume of SA (30 mg/kg, i.g) plus aspirin
(40 mg/kg, i.g), and aspirin (40 mg/kg, i.g) followed by NaHCO3 (600
mg/kg, i.g). The levels of blood glucose, 24-h urine protein, choles-
terol, triglycerides were measured and the pathological changes in the
renal tissues were examined by optical microscopy. qRT-PCR analysis
was performed to detect the renal organic anion transporters (OATs),
sodium-coupled monocarboxylate transporters (SMCTs) and uric acid
transporter 1 (URAT1). Platelet function was analyzed using ﬂow
cytometric analysis of platelet P-selectin (CD62P). Thromboxane (TX)
B2 and 6-keto-prostaglandin (PG) F1acontents were determined by
radioimmunoassay and the concentration of SA in plasma was
measured with high-performance liquid chromatography (HPLC).The
